

Table SII. Comparison of characteristics of patients based on the median neutrophil-to-lymphocyte ratio (NLR) under treatment

	NLR under treatment		Multivariate binary logistic regression			
			Initial model		Final model	
	≥ 2.15	< 2.15	Exp(B) (95% CI)	Significance	Exp(B) (95% CI)	Significance
Treatments, <i>n</i> (%)	87 (45)	108 (55)				
Age, years, mean ± SD	48.6 ± 12	46.2 ± 13	0.99 (1.0–1.0)	0.470		
Sex, female, %	38	35	0.67 (0.3–1.5)	0.338		
Psoriasis arthritis, present, %	48	43	0.83 (0.4–1.9)	0.661		
Previous systemic treatments, mean ± SD	3.0 ± 2	2.9 ± 1	0.96 (0.7–1.3)	0.769		
Median [IQR]	3.0 [2,4]	3.0 [2,4]				
Biologic, %						
TNF-α antagonist	84	92	2.82 (0.7–11.4)	0.147	3.21 (1.0–9.9)	0.041
Ustekinumab	16	8				
Concomitant methotrexate, %	13	14	1.26 (0.4–4.2)	0.708		
Treatment duration, years, mean ± SD	1.4 ± 1	2.0 ± 2	1.47 (1.0–2.1)	0.031	1.45 (1.0–2.0)	0.032
Baseline PASI, mean ± SD (<i>n</i>)	10.7 ± 7 (81)	10.0 ± 7 (101)	0.99 (0.9–1.1)	0.796		
Median [IQR]	9.3 [6,15]	9.2 [5,14]				
Baseline NLR, gmean [SD] (<i>n</i>)	4.1 [2,8] (75)	2.2 [1,3] (93)	0.46(0.3–0.6)	< 0.001	0.46(0.3–0.6)	< 0.001
Median [IQR]	3.9 [3,6]	2.1 [2,3]				

gmean: geometric mean; IQR: interquartile range; PASI: Psoriasis Area and Severity Index; SD: standard deviation; TNF-α: tumour necrosis factor-α.